Oncorus, Inc. (NASDAQ:ONCR – Get Rating) major shareholder James E. Flynn sold 141,753 shares of the stock in a transaction that occurred on Thursday, December 29th. The stock was sold at an average price of $0.26, for a total value of $36,855.78. Following the transaction, the insider now owns 299,917 shares in the company, valued at $77,978.42. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.

Oncorus Price Performance

Shares of ONCR remained flat at $0.25 during trading hours on Friday. 348,808 shares of the stock traded hands, compared to its average volume of 131,529. The company has a quick ratio of 4.97, a current ratio of 4.97 and a debt-to-equity ratio of 0.24. The company has a 50-day moving average price of $0.50 and a 200 day moving average price of $0.98. Oncorus, Inc. has a 52-week low of $0.23 and a 52-week high of $5.76.

Oncorus (NASDAQ:ONCR – Get Rating) last posted its earnings results on Wednesday, November 2nd. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.01. Equities analysts expect that Oncorus, Inc. will post -2.85 EPS for the current year.

Analyst Upgrades and Downgrades

Hedge Funds Weigh In On Oncorus

Several large investors have recently modified their holdings of the business. Goldman Sachs Group Inc. increased its stake in shares of Oncorus by 35.1% in the second quarter. Goldman Sachs Group Inc. now owns 117,925 shares of the company's stock worth $148,000 after purchasing an additional 30,668 shares in the last quarter. Millennium Management LLC purchased a new position in shares of Oncorus in the second quarter worth about $476,000. Renaissance Technologies LLC increased its stake in shares of Oncorus by 23.9% in the second quarter. Renaissance Technologies LLC now owns 217,450 shares of the company's stock worth $274,000 after purchasing an additional 41,918 shares in the last quarter. Sawtooth Solutions LLC increased its stake in shares of Oncorus by 22.9% in the second quarter. Sawtooth Solutions LLC now owns 77,336 shares of the company's stock worth $97,000 after purchasing an additional 14,433 shares in the last quarter. Finally, Private Advisor Group LLC increased its stake in shares of Oncorus by 28.9% in the second quarter. Private Advisor Group LLC now owns 81,304 shares of the company's stock worth $103,000 after purchasing an additional 18,220 shares in the last quarter. Hedge funds and other institutional investors own 63.69% of the company's stock.

Oncorus Company Profile

(Get Rating)

Oncorus, Inc, a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers.

See Also

• Get a free copy of the StockNews.com research report on Oncorus (ONCR)
• The Dogs Of Tech: It's Time For A Bite Of These Stocks
• Does This Acquisition Make Microsoft a Bear Market Buy?
• Is Kintara Therapeutics A Hidden Gem?
• Should You Warm up to Generac Stock for the Winter?
• 3 High-Yield Dividend Stocks to Hold for the Long Haul

Receive News & Ratings for Oncorus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncorus and related companies with MarketBeat.com's FREE daily email newsletter.